A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis
Key facts
- Where
- Cáceres, Córdoba, Madrid, Salamanca, and Valencia, SpainSee the 7 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 80 years old?
Source: NCT05646381, who can take part
Where in Spain
- Hospital San Pedro De AlcántaraCáceres, SpainTaking people
- Hospital Universitario Reina SofiaCórdoba, SpainTaking people
- Hospital Universitario 12 de OctubreMadrid, SpainTaking people
- Hospital Universitario La PazMadrid, SpainTaking people
- Hospital Universitario Ramón y CajalMadrid, SpainTaking people
- Hospital Universitario De SalamancaSalamanca, SpainTaking people
- Instituto De Investigacion Sanitaria Fundacion Para La Investigacion Del Hospital Clinico De Valencia-INCLIVAValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novartis Pharmaceuticals
- Trial code
- NCT05646381EU 2022-502135-19-00
- Record updated
- 23 June 2026
- Original description
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.Read full original descriptionShow less
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis [Lp(a)FRONTIERS CAVS]
The purpose of this study is to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) administered subcutaneously once monthly compared to placebo in slowing the progression of calcific aortic valve stenosis.
Inclusion: Male and female ≥50 to <80 years of age at Screening Part II; Lp(a) ≥175 nmol/L at the screening visit, measured at the Central laboratory; Mild or moderate calcific aortic valve stenosis; At the randomization visit, participant must be optimally treated for existing CV risk factors.
Exclusion: Uncontrolled hypertension; History of malignancy of any organ system; History of hemorrhagic stroke or other major bleeding; Active liver disease or hepatic dysfunction; Significant kidney disease; Platelet count ≤ LLN; Severe calcific aortic valve stenosis; Pregnant or nursing women; Other protocol-defined inclusion/exclusion criteria may apply.